Published : Nov-2021
No. of Pages : 177
1 Sepsis: Executive Summary
1.1 Sepsis Treatment to Experience Strong Growth over the Forecast Period from 2020-2030
1.2 Developers Must Leverage Innovative R&D Strategies to Target Appropriate Patients and Achieve Sustained Commercial Success
1.3 A High Level of Unmet Need Persists in the Sepsis and Septic Shock Marketplace
1.4 Opportunities Remain for Current and Future Players to Develop Therapies Targeting Sepsis-Specific Pathophysiology
1.5 Immunomodulating Therapies Poised to Transform Sepsis and Septic Shock Market, but Missing Biomarkers Will Limit Their Utility
1.6 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Overview
3.1.2 Etiology
3.1.3 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Diagnosed Incident Cases of Sepsis
4.4.4 Diagnosed Incident Cases of Sepsis by Causative Agent
4.4.5 Organ Dysfunction in Diagnosed Incident Cases of Sepsis
4.4.6 Sepsis In-Hospital Mortality Cases
4.4.7 Diagnosed Incident Cases of Septic Shock
4.4.8 Diagnosed Incident Cases of Septic Shock by Causative Agent
4.4.9 Organ Dysfunction in Diagnosed Incident Cases of Septic Shock
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Treatment Guidelines
5.3 Clinical Management of Sepsis
5.3.1 Systemic Inflammatory Response Syndrome
5.3.2 Sepsis
5.3.3 Septic Shock
5.3.4 Multiple Organ Dysfunction Syndrome
5.3.5 Nosocomial Sepsis: Healthcare-Associated and Hospital-Acquired
5.3.6 Neonatal Sepsis
5.4 Marketed Drugs by Therapeutic Class
5.4.1 Antibiotics
5.4.2 Other Anti-infective Agents
5.4.3 Vasopressors and Inotropes
5.4.4 Anticoagulants
5.4.5 Immunomodulators
5.5 Non-pharmacotherapeutic Measures for the Treatment of Sepsis
5.5.1 Mechanical Ventilation
5.5.2 Hemodialysis
5.5.3 Fluid Resuscitation
5.5.4 Blood Product Administration
5.5.5 Nutritional Accommodations for Septic Patients
5.6 Treatment of Sepsis by Geographic Region
5.6.1 US
5.6.2 5EU
5.6.3 Japan
5.7 Key Opinion Leader Insights on Disease Management
6 Competitive Assessment
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved Sepsis Education and Awareness for the Public and Healthcare Professionals
7.3 Early Recognition and Treatment of Sepsis
7.4 Improved Supportive Care for Sepsis-Induced Comorbidities
7.5 Improved Understanding of Sepsis Pathophysiology
8 R&D Strategies
8.1 Overview
8.2 Development of Sepsis Therapeutics with Diverse Mechanisms of Action
8.2.1 Coagulation System
8.2.2 Endothelium
8.2.3 Organ Damage
8.2.4 Host Immune Response
8.3 Label Expansion of Existing Marketed Drugs for Similar Indications
8.4 Collaboration, Licensing, and Partnerships
8.5 Clinical Trial Design
8.5.1 Current Clinical Trial Designs for Sepsis Drug Candidates
8.5.2 Issues with Current Clinical Trial Design for Sepsis Drug Candidates
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Clinical Trials
9.4 Early-Stage Pipeline Agents
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Clinical Benchmark of Key Pipeline Drugs
10.2.1 Clinical Benchmarking of Immunomodulators
10.2.2 Clinical Benchmarking of Vasopressors
10.2.3 Clinical Benchmarking of Antimicrobials
10.2.4 Clinical Benchmarking of Fluid Therapy
10.3 Commercial Benchmark of Key Pipeline Drugs
10.3.1 Commercial Benchmarking of Immunomodulators
10.3.2 Commercial Benchmarking of Vasopressors
10.3.3 Commercial Benchmarking of Antimicrobials
10.3.4 Commercial Benchmarking of Fluid Therapies
10.4 Competitive Assessment
10.4.1 Competitive Assessment of Immunomodulators
10.4.2 Competitive Assessment of Vasopressors
10.4.3 Competitive Assessment of Antimicrobials
10.4.4 Competitive Assessment of Fluid Therapy
11 Current and Future Players
12 Market Outlook
13 Appendix
List of Tables
Table 1: Sepsis: Key Metrics in the 7MM
Table 2: Stages of Sepsis, According to SSC Guidelines
Table 3: Risk Factors and Comorbidities for Sepsis and Septic Shock
Table 4: Criteria Used for SOFA Score in the Diagnosis of Sepsis
Table 5: Treatment Guidelines for Sepsis in the 7MM
Table 6: Commonly Used Antibiotics in Sepsis and Septic Shock and Corresponding Gaps in Coverage
Table 7: Examples of Supportive Therapies for Patients with Sepsis or Septic Shock
Table 8: Sepsis Disease Management - US
Table 9: Sepsis Disease Management - 5EU
Table 10: Sepsis Disease Management - Japan
Table 11: Marketed Therapies for Sepsis Across the 7MM
Table 12: Collaboration, Licensing and Deals of Sepsis Drug Candidates
Table 13: Clinical Trial Designs for Sepsis Pipeline Drug Candidates
Table 14: Innovative Early-Stage Approaches for Sepsis, 2021
Table 15: Clinical Benchmark of Key Marketed and Pipeline Drugs - Immunomodulators in Sepsis
Table 16: Clinical Benchmark of Key Marketed and Pipeline Drugs - Vasopressors in Sepsis
Table 17: Clinical Benchmark of Key Marketed and Pipeline Drugs - Antimicrobials in Sepsis
Table 18: Clinical Benchmark of Key Marketed and Pipeline Drugs - Fluid Therapy in Sepsis
Table 19: Commercial Benchmark of Key Marketed and Pipeline Drugs - Immunomodulators in Sepsis
Table 20: Commercial Benchmark of Key Marketed and Pipeline Drugs - Vasopressors in Sepsis
Table 21: Commercial Benchmark of Key Marketed and Pipeline Drugs - Antimicrobials in Sepsis
Table 22: Commercial Benchmark of Key Marketed and Pipeline Drugs - Fluid Therapy in Sepsis
Table 23: Adrenomed's Sepsis Portfolio Assessment, 2021
Table 24: AM-Pharma's Sepsis Portfolio Assessment, 2021
Table 25: Asahi Kasei Pharma's Sepsis Portfolio Assessment, 2021
Table 26: Grifols' Sepsis Portfolio Assessment, 2021
Table 27: Inotrem's Sepsis Portfolio Assessment, 2021
Table 28: La Jolla's Sepsis Portfolio Assessment, 2021
Table 29: Merck's Sepsis Portfolio Assessment, 2021
Table 30: Pfizer's Sepsis Portfolio Assessment, 2021
Table 31: RevImmune's Sepsis Portfolio Assessment, 2021
Table 32: Sanofi's Sepsis Portfolio Assessment, 2021
Table 33: Takeda's Sepsis Portfolio Assessment, 2021
Table 34: Sepsis Market - Global Drivers and Barriers, 2020-2030
Table 35: Key Events Impacting Sales for Sepsis in the US, 2020-2030
Table 36: Sepsis Market - Drivers and Barriers in the US, 2020-2030
Table 37: Key Events Impacting Sales for Sepsis in the 5EU, 2020-2030
Table 38: Sepsis Market - Drivers and Barriers in the 5EU, 2020-2030
Table 39: Key Events Impacting Sales for Sepsis in Japan, 2020-2030
Table 40: Sepsis Market - Drivers and Barriers in Japan, 2020-2030
Table 41: Key Projected Launch Dates for Sepsis and Septic Shock
Table 42: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Sepsis in 2020 and 2030
Figure 2: Company Portfolio Gap Analysis in Sepsis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Sepsis During the Forecast Period
Figure 4: Pathophysiological Features of Sepsis
Figure 5: 7MM, Diagnosed Incidence of Sepsis, All Ages, Men and Women, Cases per 100,000 Population, 2010?2030
Figure 6: 7MM, Diagnosed Incidence of Septic Shock, All Ages, Men and Women, Cases per 100,000 Population, 2010?2030
Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Incident Cases of Sepsis
Figure 8: 7MM, Sources Used for the Diagnosed Incident Cases of Septic Shock
Figure 9: 7MM, Sources Used for the Diagnosed Incident Cases of Sepsis/Septic Shock by Causative Agents
Figure 10: 7MM, Sources Used for Organ Dysfunction in the Diagnosed Incident Cases of Sepsis
Figure 11: 7MM, Sources Used for Organ Dysfunction in the Diagnosed Incident Cases of Septic Shock
Figure 12: 7MM, Sources Used and Not Used for Sepsis/Septic Shock In-Hospital Mortality Cases
Figure 13: Overview of Treatment Options for Sepsis and Septic Shock
Figure 14: Unmet Needs and Opportunities in Sepsis and Septic Shock
Figure 15: Overview of the Global Development Pipeline in Sepsis
Figure 16: Key Clinical Trials for Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for Sepsis During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Sepsis During the Forecast Period
Figure 18: Competitive Assessment of RecAP and CYT107, the Pipeline Therapies for Immunomodulation in Sepsis, Benchmarked against the SOCs, Hydrocortisone and IVIg
Figure 19: Competitive Assessment of Motrem and Adrecizumab, the Pipeline Therapies for Vasopressors in Sepsis, Benchmarked against the SOC, Norepinephrine
Figure 20: Competitive Assessment of Cefiderocol, the Pipeline Therapy for Antimicrobials in Sepsis, Benchmarked against the SOC, Meropenem
Figure 21: Competitive Assessment of Human Albumin, the Pipeline Therapy for Fluid Therapy in Sepsis, Benchmarked against the SOC, Ringer's lactate
Figure 22: Company Portfolio Gap Analysis in Sepsis, 2020-2030
Figure 23: Global (7MM) Sales Forecast by Country for Sepsis in 2020 and 2030
Figure 24: Sales Forecast by Class for Sepsis in the US in 2020 and 2030
Figure 25: Sales Forecast by Class for Sepsis in the 5EU in 2020 and 2030
Figure 26: Sales Forecast by Class for Sepsis in Japan in 2020 and 2030
